Elevance Health, Inc. (ELV) Form 8-K — Oct 21, 2026
Elevance Health reported Q3 2026 results ahead of expectations, with operating revenue of $50.4 billion (+0.7% YoY), diluted EPS of $6.27, and adjusted diluted EPS of $6.99, up 15.9% year over year. The company raised full-year 2026 guidance to at least $22.00 diluted EPS and at least $29.00 adjusted diluted EPS, with operating cash flow guidance raised to at least $6.5 billion, and expects at least 12% adjusted EPS growth in 2027.
Key figures
- Eps
- 6.27
- Revenue
- 50440000000
- Guidance
- FY2026 diluted EPS at least $22.00; adjusted diluted EPS at least $29.00; operating cash flow at least $6.5 billion; at least 12% adjusted diluted EPS growth in 2027 from baseline of at least $26.75
- Net Income
- 1365000000
- Revenue Yoy
- 0.7%
- Total Assets
- 127801000000
- Cash Position
- 10348000000
- Shares Outstanding
- 217600000
- Q3 buyback
- $330 million (0.8M shares at avg $398.75)
- Cms accrual
- $935 million
- Dividend per share
- 1.72
- Medical membership
- 44.9 million
- Parent company cash
- $2.4 billion
- Adjusted diluted eps
- 6.99
- Benefit expense ratio
- 90.6%
- Days in claims payable
- 44.9
- Carelon operating gain growth
- 17%
- Adjusted shareholders net income
- 1520000000
- Repurchase authorization remaining
- $5.0 billion
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.